雾化吸入重组人干扰素α1b治疗儿童呼吸系统疾病的效果

Effectiveness of Nebulized Inhalation of Recombinant Human Interferonα1b in the Treatment of Respiratory Diseases in Children

目的:分析采取雾化吸入重组人干扰素α1b治疗儿童呼吸系统疾病的价值。方法:选取2021年8月—2022年8月深圳市龙岗区第二人民医院中海怡翠社区健康服务中心收治的呼吸系统疾病患儿100例为研究对象,采用随机数字表法分为对照组和研究组,各50例。对照组接受常规治疗,研究组在对照组基础上给予重组人干扰素α1b雾化吸入治疗。比较两组治疗总有效率、症状改善时间及免疫球蛋白水平。结果:研究组治疗总有效率高于对照组,差异有统计学意义(P=0.037);研究组肺部啰音消失时间、憋喘消失时间、咳嗽消失时间、咽喉肿痛消失时间、发热消失时间短于对照组,差异有统计学意义(P<0.001);治疗后,两组免疫球蛋白A、免疫球蛋白M、免疫球蛋白G水平升高,研究组高于对照组,差异有统计学意义(P<0.05)。结论:雾化吸入重组人干扰素α1b应用于儿童呼吸系统疾病治疗中,有助于缩短患儿临床症状恢复时间,提高机体免疫球蛋白水平,临床治疗效果较好。

Objective:To analyze the value of taking nebulized inhalation of recombinant human interferonα1b for the treatment of respiratory diseases in children.Methods:One hundred children with respiratory diseases admitted to Zhonghai Yicui Community Health Center of Shenzhen Longgang District Second People's Hospital from August 2021 to August 2022 were selected as the study subjects,and were divided into a control group and a study group of fifty cases each by using the random number table method.The control group received conventional treatment,and the study group was given recombinant human interferonα1b nebulized inhalation treatment on the basis of the control group.The total effective rate,symptom improvement time and immunoglobulin level were compared between the two groups.Results:The total effective rate of treatment in the study group was higher than that in the control group,and the difference was statistically significant(P=0.037);the time for the disappearance of lung rales,the time for the disappearance of breath-holding,the time for the disappearance of cough,the time for the disappearance of sore throat,and the time for the disappearance of fever in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.001);after treatment,the levels of immunoglobulin A,immunoglobulin M and immunoglobulin G increased in the two groups,and the study group was higher than the control group,and the difference was statistically significant(P<0.05).Conclusion:Nebulized inhalation of recombinant human interferonα1b applied in the treatment of respiratory diseases in children can help to shorten the recovery time of children's clinical symptoms,improve the level of immunoglobulin,and the clinical therapeutic effect is better.